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AbstrAct
background: currently, cBcT system is an indispensable component of radiation therapy units. Because of that, it is impor-
tant in treatment planning and diagnosis. cBcT is also an crucial tool for patient positioning and verification in image-guided 
radiation therapy (IGrT). Therefore, it is critical to investigate the patient organ doses arising from cBcT imaging. The purpose 
of this study is to evaluate patient organ doses and effective dose to patients from three different protocols of elekta synergy 
XVI system for kV cBcT imaging examinations in image guided radiation therapy.
Materials and methods: Organ dose measurements were done with thermoluminescent dosimeters in alderson raNDO 
male phantom for head & neck (h&N), chest and pelvis protocols of the elekta synergy XVI kV cBcT system. From the measured 
organ dose, effective dose to patients were calculated according to the International commission on radiological protection 
103 report recommendations. 
results: For h&N, chest and pelvis scans, the organ doses were in the range of 0.03–3.43 mGy, 6.04–22.94 mGy and 2.5–25.28 
mGy, respectively. The calculated effective doses were 0.25 msv, 5.56 msv and 4.72 msv, respectively. 
conclusion: The obtained results were consistent with the most published studies in the literature. although the doses to 
patient organs from the kV cBcT system were relatively low when compared with the prescribed treatment dose, the amount 
of delivered dose should be monitored and recorded carefully in order to avoid secondary cancer risk, especially in pediatric 
examinations.
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Cancer is still accepted as the deadliest among 
all diseases [1]. In order to cure cancer, several 
treatment modalities have been used in recent 
years. Radiation therapy is one of the main treat-
ment methods used in cancer treatment  along with 
surgery and chemotherapy. Especially, when the 
surgery and chemotherapy are not feasible, radia-
tion therapy is the only treatment choice for some 
cancer forms. Additionally, due to the vital status of 
radiation therapy in many cancer types, treatment 
delivery accuracy of radiation therapy becomes 
critical for cancer patients [2]. One of the most 
important factors that make cancer treatment ef-
ficacious is irradiation of the targeted tumor tissue 
under appropriate conditions, as well as protecting 
normal tissues surrounding the tumor as much as 
possible. It is essential that the patient is positioned 
correctly before and during the treatment in order 
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to get favorable results [3]. The first step of treat-
ment delivery is correct positioning of the patient 
on a treatment couch. Although the technician can 
align the patient on the treatment couch correctly 
from the external perspective; the position of nor-
mal tissues or tumor may not be as they should be 
from the internal point of view. For this reason, 
imaging the corresponding part of the treatment 
region before treatment is prerequisite for perfect 
treatment delivery. 
Nowadays, image guided radiation therapy 
(IGRT) is accepted to be the standard treatment 
modality especially for challenging treatment 
cases and, especially, for arc therapy. Generally, 
Cone Beam Computed Tomography (CBCT) is 
believed to be one of the most useful imaging 
methods in radiation therapy. Moreover, CBCT 
is not only used in cancer treatment for imaging 
head& neck (H&N), thorax and pelvis regions, 
but also used in the examination of the man-
dible and nasal region in dentistry. Commonly, 
CBCT imaging systems are named in terms of the 
energies produced by the X-ray generator dur-
ing imaging processes. The platforms which use 
million-voltage (MV) X-ray energies for imaging 
are called MV-CBCT. On the other hand, some of 
the systems use kilo-voltage (kV) X-ray energies 
for this process and these platforms are named 
kilo-voltage CBCT (kV-CBCT). They consist of 
a kV generator that produces X-rays in kilo-volt 
energies and a flat-panel detector, most often 
called electronic portal imaging device (EPID), 
that detects these attenuated X-rays. During the 
imaging process the kV-generator and flat-panel 
detector complete their rotation around the cor-
responding region of the body by obtaining high 
quality projection data [3–5].
Verifying position accuracy before and during 
the treatment of the patient is done by analyzing 
simultaneous images taken of the patient with the 
help of electronic portal imaging devices. EPID is 
a part of digital radiography that provides ease of 
use in imaging technology and equipped with the 
latest technological developments. In addition to 
AP and LAT images that are used conventionally 
at 90 degrees angle to each other, it is important 
to obtain a 3-dimensional image in order to estab-
lish patient position accuracy in all axes by using 
EPID [6]. On the other hand, beside having many 
advantages, the main disadvantage of this imaging 
system is delivering undesired radiation dose to the 
patient. The repeated use of a CBCT system in all 
fractions of treatment could increase the probabil-
ity of developing secondary cancer risk, especially 
in pediatric patients [7, 8]. Because of that, these 
imaging systems should be used carefully and the 
additional undesired imaging dose to patient or-
gans should be monitored and measured.
The purpose of this study is to evaluate patient 
organ doses from three different protocols of the 
Elekta Synergy XVI system for kV CBCT imaging 
examinations in image guided radiation therapy 
using Alderson Rando male phantom. In addition 
to that, from the measured organ doses, effective 
dose to patients were calculated by using ICRP 103 
recommendations.
Materials and methods
The measurements of patient organ doses from 
kV-CBCT scans were collected by using Elekta 
Synergy Platform that was equipped with X-ray 
Volume Imaging (XVI) system release 4.5 (Elek-
ta Oncology Systems Ltd, Crawley, UK) (Fig. 1). 
The X-ray source is attached to a retractable arm 
with a fixed source to isocenter distance of 100 cm 
(Fig. 1). 
Imaging process and measurements
For H&N, thoracic and pelvic scans; Head & 
Neck S20, Chest M20 and Pelvis M20 presets were 
performed, respectively. The field of view in axial 
and longitudinal axis were described in detail in 
the study of Hyer et al. [9]. Moreover, the detailed 
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parameters for each imaging protocol are listed in 
Table 1. 
In this study a total of 20 patient organ dose 
measurements were carried out in an Alderson 
Rando anthropomorphic male phantom (Phantom 
Laboratory, Salem, NY, USA). In addition to that, 
effective doses to the patient were calculated from 
the measured organ doses. The detailed list of or-
gans measured in the study is displayed in Table 2. 
In the Alderson Rando phantom, soft tissue, bone 
and lungs are equivalent to their true density. The 
bones in the Rando phantom are real human bones, 
and there are cavities equivalent to those in human 
body. The male RANDO phantom is made of 36 
slices, each with a thickness of 2.5 cm, except for 
slice 35 which is 9 cm thick. Each slice from slice 
number 1 to 34 contains a grid of holes, 5 mm in 
diameter, separated at 3 cm distance (Fig. 2).The 
positions of TLDs in the RANDO phantom were 
positioned in consistence with the recommenda-
tions of Golikov&Nikitin and Scalzetti [10, 11]. 
The measurements were repeated three times for 
each scanning protocol. The arithmetic mean of 
these measurements was recorded as the average 
dose for the corresponding organ. The mean dose 
and standard deviation for each measurement were 
calculated by using the SPSS software version 22 
(Armonk, NY, IBM Corp., USA).
table 1. exposure parameters for kV cBcT scanning protocols
Head & Neck S20 Chest M20 Pelvis M20
X-ray voltage [kVp] 100 120 120
X-ray [mas] 36.6 1056 1056
Gantry rotation [degree] 360 360 360
Nominal projection number 366 660 660
table 2. The measured organ doses (mGy) and calculated effective dose to patient (msv) from single kV cBcT scan
Organ Head & neck scan Chest scan Pelvic scan
Brain 2.80 ± 0.01
Oral mucosa 3.25 ± 0.01
salivary gland 3.18 ± 0.02
Thyroid 3.23 ± 0.01
Lens 3.43 ± 0.03
esophagus 0.73 ± 0.02 15.04± 0.08
Lungs 0.03 ± 0.00** 17.83 ± 0.08
Thymus 17.93 ± 0.09
spleen 15.26 ± 0.08
heart 22.94 ± 0.10
adrenals 11.93 ± 0.06
skin 0.29 ± 0.00 ** 8.22 ± 0.04 2.89 ± 0.02
Liver 15.77 ± 0.07 2.50 ± 0.02
stomach 11.70± 0.06 5.18 ± 0.03
Kidneys 6.04 ± 0.03 13.10 ± 0.05
pancreas 7.88 ± 0.04 7.43 ± 0.04
Gall bladder 23.52 ± 0.09
small intestine 25.28 ± 0.09
colon 24.25 ± 0.09
Bladder 11.53 ± 0.07
effective dose 0.25* 5.56* 4.72*
*Denotes underestimated effective doses for each scan (some of the organs with tissue factor couldn’t be measured); **Denotes the standard deviation is less 
than 0.01
Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 2
https://journals.viamedica.pl/rpor254
Scalzetti et al. offered a new proposal about the 
hole position of organs in the Alderson Rando 
phantom based on three-dimensional Cartesian 
coordinate system. According to that conjecture, 
the center hole of each slice was accepted as the 
(0,0) central point in a rectangular frame (Fig. 3).  
Lens and skin doses were measured by placing 
TLD on the surface of corresponding part of the 
phantom. Eight TLDs were used to compute the 
skin doses in each preset by locating the TLDs in 
the anterior, posterior, left and right surface of the 
phantom.
TLD calibration
Before starting the calibration process, Ele-
ment Correction Coefficient (ECC) factors were 
calculated for each thermoluminescent dosimeter 
(TLD), and the TLDs which are within ± 5% ac-
ceptance limit were selected for use. In total, 116 
lithium fluoride TLDs (TLD-100 LiF) were used for 
each measurement. The TLDs used are in the form 
of a square prism with dimensions 3.2 mm × 3.2 
mm × 0.9 mm. In order to make the measure-
ments more accurate, each TLD has been calibrated 
individually before measurements for the photon 
energy of 100 kVp and 120 kVp. Same beam pa-
rameters were used for the calibration as during 
the measurements (Fig.  4). TLDs were irradiated 
in a poly-methyl methacrylate holder. After that, 
irradiated TLDs were read with Harshaw 3500 TLD 
reader (Harshaw Thermo Electron, Solon, USA). 
From the beam and dose parameters used in the 
calibration process (mAs, mGy), Reader Calibra-
tion Factor (RCF) was computed for each scanning 
protocol which was used in the calculation proce-
dure of patient organ doses.
calculation of organ doses  
and effective dose
Patient organ dose measurements were carried 
out in an Alderson Rando anthropomorphic male 
phantom by TLD placed in hole positions of organs. 
The definition of equivalent dose is based on the 
mean absorbed dose, DT , in the volume of a speci-
fied organ or tissue T, due to radiation of type R 
[12]. The unit of absorbed dose is Gray (Gy). The 
mean absorbed dose, DT to a specific organ or tissue 
T, is calculated by using equation 1 [12].
Figure 2. alderson rando male phantom 
Figure 3. center hole in cartesian coordinate system 
assigned by scalzetti et al. and hole numbers logic in 
alderson rando phantom (e.g. slice 31) 
Figure 4. calibration process of LiF TLDs 
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DT = ∑i  Di fi         (1)
where DT denotes the mean absorbed dose of the 
specified organ in miligray (mGy), Di is the arith-
metic mean dose of the TLDs for the correspond-
ing organ within the slice i of phantom, fi denotes 
the fraction of total organ mass in the slice i of the 
Alderson RANDO phantom. Equivalent dose in 
an organ or tissue, HT, is then defined by equation 
2 [12]:
HT =∑R wR DT         (2)
where wR is the radiation weighting factor for 
radiation R. Radiation weighting factor is equal to 
one for photons [12].
After calculating patient equivalent organ dos-
es (HT), effective dose (Deff) were computed in 
milisievert (mSv) by using Equation 3 which is de-
fined by the International Commission on Radio-
logical Protection (ICRP). The effective dose, Deff, 
is defined by a weighted sum of organ or tissue 
equivalent doses [12].
Deff = ∑T wT HT         (3)
where wT is the tissue weighting factor prescribed 
by ICRP [12]. 
In this study, the tissue weighting factors, which 
were suggested in the ICRP 103 publication, were 
used [12]. In addition to that, 0.0086 value was 
assigned for remainder organs as suggested by the 
ICRP 103 publication. Besides, while in the ICRP 
60 report, the upper large intestine (ULI) was in-
cluded in remainder organs, in the ICRP 103 re-
port, the upper large intestine and lower large in-
testine (LLI) were combined and named as colon. 
Moreover, in this study, while calculating the colon 
dose, the formula suggested in the ICRP 67 report 
was used, which is mass weighted average of the 
doses of both ULI and LLI as Colon Dose = 0.57 
ULI + 0.43 LLI [12–14].
Fraction values of the skin were obtained from 
the study of Huda & Sandison [15]. All the other or-
gans fractions were reported in literature. Because 
of the lack of information about the hole location 
for red bone marrow (RBM) and bone surface in 
the RANDO phantom, the equivalent doses were 
not able to be measured for these organs. In addi-
tion to that, since an Alderson RANDO male phan-
tom was used, the breast dose was not measured. 
Moreover, because of the gonads were out of the 
beam line in pelvic irradiation, the equivalent dose 
of the gonads was not calculated. As a result, the 
effective dose was underestimated for the patient.
results
The maximum organ dose for H&N, thoracic 
and pelvic scans were at the lens, heart and small 
intestine, with equivalent doses value of 3.43 mGy, 
22.94 mGy and 25.28 mGy, respectively. The cal-
culated effective dose to the patient for H&N S20, 
Chest M20 and Pelvis M20 were 0.25 mSv, 5.56 mSv 
and 4.72 mSv, respectively.  The measured organ 
doses and calculated effective dose to the patient are 
displayed in Table 2.
Discussion
Position accuracy, which is among the most de-
termining factors that affect the quality of treat-
ment, is performed in a flawless manner with de-
vices using advanced technology such as CBCT. 
Because of that, CBCT is of critical importance 
in today’s radiotherapy treatment, and researchers 
have examined the quality assurance parameters of 
this system from the beginning of implementation 
[16–21]. 
On the other hand, beside this unique properties 
of CBCT, delivering to the patient an additional 
dose for this procedure is its major drawback. In 
this study, the absorbed organ doses and the effec-
tive dose given to the patient were measured on an 
Alderson RANDO phantom for the imaging proto-
cols applied to different parts of the body using the 
kV CBCT imaging system on the Elekta Synergy 
Platform.
The organ doses highly rely on exposure param-
eters and the geometry of the scanning procedure, 
such as field of view size and depth of measure-
ment. In literature, a large spectrum of research 
has been conducted. Although most of the studies 
were carried out with similar exposure parameters, 
a considerable number of them applied different 
scanning parameters.
Most of the recent studies have indicated that 
secondary cancer risk due to X-ray exposure from 
diagnostic imaging of the CBCT systems is more 
than anticipated, especially for pediatric patients [7].
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In this study, the calculated doses were just for 
a single course of an imaging process. Because of 
that, treatment delivery dose of radiation therapy 
may differ for different types of cancer and the total 
imaging dose for the entire course of radiotherapy 
might be increased. In other words, for a single 
patient, the obtained values in Table 2 could be 
multiplied by the total fraction number of the ra-
diotherapy. In such case, the dose taken from the 
imaging process could rise to higher values during 
the course of treatment.
Hyer et al. measured effective dose with opti-
cal-fiber based scintillation detectors for the Elekta 
Synergy XVI system. It was one of the most com-
prehensive study in literature for investigating the 
organ doses from CBCT imaging. Although similar 
exposure parameters for H&N and Chest kV CBCT 
irradiations were used; our results in this study 
are different. In the chest scanning protocol, the 
organs doses, such as the heart, lung, liver, stomach 
and kidney, were calculated to be lower. In addi-
tion, while the dose to the esophagus was found 
to be close to the measured value in this study; the 
thyroid dose was calculated higher as 19.24 mGy. 
On the other hand, all measured organ doses for 
H&N scanning protocol were lower than that of 
those calculated in this study. Furthermore, the ef-
fective dose measurements reported for H&N and 
Chest irradiation were consistent with the findings 
of our study which were 0.04 mSv and 7.15 mSv, 
respectively [9].
Remarkably, although higher exposure param-
eters were applied for H&N imaging in the study of 
Amer et al., the obtained surface dose of the phan-
tom was consistent with our study [22]. 
A feasibility study was carried out for the Elekta 
Synergy XVI system on the Alderson rando phan-
tom by Sykes et al. In that study, the image quality 
and the delivered dose values were compared in 
high exposure and low exposure scanning modes. 
In H&N imaging, it was reported that surface and 
internal absorbed dose values were measured to be 
about 1 mGy, which was performed with the same 
exposure parameters in this study. The resultant 
values were approximately 1 in 3 of the values ob-
tained in the present study [23].  
Moon et al. used glass dosimeters to measure 
patient organ doses in a RANDO female phantom 
with the same exposure parameters and scanning 
geometry for the chest and pelvic scan of the cur-
rent study. The reported organ doses were in good 
agreement with those obtained from this study for 
the chest scan, particularly for the lungs, stomach, 
liver and thymus. On the other hand, the doses 
measured from the pelvic scan were lower for al-
most all specified organs. Nevertheless, the effec-
tive dose value for the pelvic scan was completely 
consistent with this study, which was 4.09 mSv. The 
underlying reason for that consequence can be that 
the number of tissues included in the calculation 
was higher than that of our study [24]. 
Dufek et al. evaluated and compared the organ 
and effective doses for different version of OBI and 
XVI systems in an Alderson RANDO male phan-
tom by using a great number of TLDs. Although the 
exposure parameters for H&N scans were similar, 
the calculated organ doses were lower than this 
study. The doses for most of the organs in the H&N 
region were lower than 0.1 mGy in that study. The 
maximum organ doses reported for the salivary 
gland and oral mucosa as 0.9 mGy and 1.1 mGy, 
respectively. These measured doses were lower than 
the doses obtained in this study, i.e. about 3 mGy 
[25]. 
In this study, similar to the studies in the lit-
erature, it is shown that decreasing dose parameter 
values, particularly mAs and the projection num-
bers, are critical factors in the reduction of the dose 
delivered to the patient.
It should be noted that during the imaging pro-
cess, trading off image quality in order to give the 
patient lower dose may cause repeat imaging. In 
other words, it is important to be able to achieve 
the “As low as diagnostically acceptable” (ALADA) 
principle without ignoring the “As low as reason-
ably achievable” (ALARA) principle. This under-
standing will allow both the reduction of the dose 
given to the patient and an imaging procedure with 
sufficient imaging quality.
conclusions
In this study, the equivalent doses of 20 organs 
and effective dose to patients were measured with 
TLDs in an Alderson RANDO male phantom for 
Elekta Synergy XVI system with the most used clin-
ical protocols of kV CBCT. The equivalent organ 
doses and effective doses were estimated according 
to the ICRP 103 recommendations. The obtained 
findings were consistent with most of the published 
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results in literature. Although the doses to patient 
organs from the kV CBCT system were relatively 
low when compared with the prescribed treat-
ment dose, the amount of delivered dose should 
be monitored and recorded carefully in order to 
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